Abstract
Obesity is the most important modifiable risk factor for type 2 diabetes mellitus and most patients with diabetes are overweight or obese. It is well known that excess bodyweight induces or aggravates insulin resistance, which is a characteristic feature of type 2 diabetes. Thus, bodyweight plays a central role in the prevention and treatment of diabetes. Recent data suggest that lifestyle intervention in patients with impaired glucose tolerance results in an impressive reduction in the conversion to overt diabetes, which is greater than the effect of early intervention with drugs such as metformin or acarbose. The prevention of diabetes has been shown to be associated with the extent of weight loss. In patients with type 2 diabetes, weight loss by any means is followed by an improvement of metabolic control and associated risk factors. The most appropriate recommendation for obese patients with type 2 diabetes is a nutritionally balanced, moderately hypocaloric diet with a reduced intake of saturated fat and an increase in physical activity. If this standard approach is only partly successful or not at all, additional strategies such as weight-lowering drugs, very low-calorie diets for limited periods of up to 12 weeks, and, for severely obese patients, bariatric surgery should be carefully considered. A large body of data suggests that such measures can be very effective in this patient group by improving metabolic disturbances and blood pressure. However, it is extremely important for the long-term outcome that the treatment is tailored to the needs and wishes of the individual patient. There is growing agreement that due to the low success rate of conventional therapies and the overwhelming benefit from weight loss, more determined and aggressive strategies may be appropriate to achieve the central goal of weight reduction in obese patients with type 2 diabetes.
Similar content being viewed by others
References
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414–31
World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Technical Report Series 894. Geneva: World Health Organization, 2000
Colditz GA, Willett WC, Rotznitzky A, et al. Weight gain as a risk factor for clinical diabetes in women. Ann Intern Med 1995; 122: 481–6
Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961–9
Hartz AJ, Rupley DC, Kalkhoff RK, et al. Relationship of obesity to diabetes: influence of obesity level and body-fat distribution. Prev Med 1983; 12: 351–7
Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 74:761–811
Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790–7
Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–5
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403
Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2001; 359: 2072–7
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53
Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321–6
Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–62
Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003
Harris IM, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4–7 years before clinical diagnosis. Diabetes Care 1992; 15: 815–9
Hanefeld M, Fischer S, Schmechel H, et al. Diabetes intervention study: multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991; 14: 308–17
European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716–30
American Diabetes Association. American Diabetes Association Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. J Am Diet Assoc 2002; 102: 109–18
Brown SA, Winter M, Upchurch S, et al. Promoting weight loss in type II diabetes. Diabetes Care 1996; 19: 613–24
Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749–53
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53
Kronsbein P, Jörgens V, Mühlhauser I, et al. Evaluation of a structured treatment and teaching programme on non-insulin-dependent diabetes mellitus. Lancet 1988; II: 1407–11
Wing RR. Behavioral treatment of obesity: its application to type II diabetes. Diabetes Care 1993; 16: 193–9
Wadden TA, Berkowitz RI, Vogt RA, et al. Lifestyle modification in the pharmacological treatment of obesity: a pilot investigation of a potential primary care approach. Obes Res 1997; 5: 218–26
Watts NB, Spanheimer RG, DiGirolamo M, et al. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. JAMA 1990; 150: 803–6
Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991; 14: 802–23
Wing RR, Blair E, Marcus M, et al. Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 1994; 97: 354–62
Williams KV, Kelley DE, Mullen ML, et al. The effect of short-term periods of caloric restriction on weight loss and glycemic control in type 2 diabetes. Diabetes Care 1998; 21: 2–8
Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74: 579–84
Wadden TA, van Itallie TB, Blackburn GL. Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity. JAMA 1990; 263: 2885–7
Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 1986; 35: 990–8
Henry RR, Schaefer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985; 61: 917–25
Kelley DE, Wing R, Buonocore C, et al. Relative effects of calorie restriction and weight loss in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1287–93
Felber JP, Meyer HU, Curchod B, et al. Effect of a 3-day fast on glucose storage and oxidation in obese hyperinsulinemic diabetics. Metabolism 1981; 30: 184–9
Hughes TA, Gwynne JT, Switzer BR, et al. Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. Am J Med 1984; 77: 7–17
Hauner H, Meier M, Wendland G, et al. Weight reduction by sibutramine in obese subjects in primay care medicine: the s. A. T. Study. Exp Clin Endocrinol Diabetes 2004 Apr; 112(4): 201–7
Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001 Sep 19; 286(11): 1331–9
James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000 Dec 23–30; 356(9248): 2119–25
McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56: 1093–124
Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000; 2: 1–8
Gokcel A, Tanaci N, Karakose H, et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 1957–60
Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999; 58: 743–60
Hollander PA, Kaplan RA, Elbein SC, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288–94
Kelley DE, Hill J, Bray GA, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002; 25: 1033–41
Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA 1998; 280: 140–6
Yki-Järvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 4037–43
Johanson K. Efficacy of metformin in the treatment of NIDDM. Diabetes Care 1999; 22: 33–7
Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18: S10–5
Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507–14
Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339–52
Dixon JB, O’Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002; 25: 358–63
MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213–20
Henry RR, Wiest-Kent TA, Schaefer L, et al. Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects. Diabetes 1986; 35: 155–64
Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight non-diabetic spouses. Diabetes Care 1987; 10: 214–27
Guare JC, Wing RR, Grant A. Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res 1995; 3: 329–35
Kahn MA, Peter JV, Breen GA, et al. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants. Obes Res 2000; 8: 43–8
Dixon JB, Dixon ME, O’Brien PE. Pre-operative predictors of weight loss at 1-year after lap-band surgery. Obes Surg 2001; 11: 200–7
Wing RR, Marcus MD, Salata R, et al. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Intern Med 1991; 151: 1334–40
Manning RM, Jung RT, Leese GP, et al. The comparison of four weight reduction strategies aimed at overweight patients with diabetes mellitus: four-year follow-up. Diabet Med 1998; 15: 497–502
Perri MG, Sears SF, Clark JE. Strategies for improving maintenance of weight loss: towards a continuous care model of obesity management. Diabetes Care 1993; 16: 200–9
Acknowledgments
The author has provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hauner, H. Managing Type 2 Diabetes Mellitus in Patients with Obesity. Mol Diag Ther 3, 223–232 (2004). https://doi.org/10.2165/00024677-200403040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024677-200403040-00004